Cassava Sciences, Inc. (SAVA)

NASDAQ: SAVA · IEX Real-Time Price · USD
+3.29 (9.79%)
At close: Dec 7, 2022 4:00 PM
-0.41 (-1.11%)
After-hours: Dec 7, 2022 7:52 PM EST

Company Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.

Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.

Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences, Inc.
Cassava Sciences logo
Country United States
Founded 1998
Industry Pharmaceuticals
Sector Health Care
Employees 24
CEO Remi Barbier

Contact Details

6801 N Capital Of Texas Highway, Building 1; Suite 300
Austin, Texas 78731
United States
Phone 512-501-2444

Stock Details

Ticker Symbol SAVA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001069530
CUSIP Number 14817C107
ISIN Number US14817C1071
Employer ID 91-1911336
SIC Code 2834

Key Executives

Name Position
Remi Barbier Founder, Chairman, President and Chief Executive Officer
Eric J. Schoen Chief Financial Officer
Dr. Nadav Friedmann M.D., Ph.D. Chief Medical Officer and Director
Dr. James W. Kupiec M.D. Chief Clinical Development Officer
Dr. George Thornton Senior Vice President of Technology
Christopher Cook Senior Vice President and General Counsel
Michael Zamloot Senior Vice President of Technical Operations
Dr. Lindsay H. Burns Ph.D. Senior Vice President of Neuroscience

Latest SEC Filings

Date Type Title
Nov 22, 2022 8-K Current Report
Nov 21, 2022 424B5 Filing
Nov 7, 2022 10-Q Quarterly Report
Nov 7, 2022 8-K Current Report
Nov 3, 2022 8-K Current Report
Oct 27, 2022 8-K Current Report
Sep 23, 2022 8-K Current Report
Aug 4, 2022 10-Q Quarterly Report
Aug 3, 2022 8-K Current Report
Jul 29, 2022 424B5 Filing